BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+3.62%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$22.8B
AUM Growth
+$22.8B
(-1.3%)
Cap. Flow
-$610M
Cap. Flow
% of AUM
-2.68%
Top 10 Holdings %
Top 10 Hldgs %
81.57%
Holding
135
New
6
Increased
16
Reduced
10
Closed
15
Top Buys
| 1 |
VERV
Verve Therapeutics
VERV
|
$85.3M |
| 2 |
Legend Biotech
LEGN
|
$63.6M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$37.8M |
| 4 |
Heron Therapeutics
HRTX
|
$33.2M |
| 5 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$32.6M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$611M |
| 2 |
NVTA
Invitae Corporation
NVTA
|
$186M |
| 3 |
Protagonist Therapeutics
PTGX
|
$44M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$33.7M |
| 5 |
Altimmune
ALT
|
$16.6M |
Sector Composition
| 1 | Healthcare | 97.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cerus
CERS
$251M
| $81M | 0.36% |
13,713,195
| – | – |
|
|
DBVT
27
DBV Technologies
DBVT
$249M
| $79.8M | 0.35% |
14,614,264
| – | – |
|
28
Rhythm Pharmaceuticals
RYTM
$6.75B
| $75.6M | 0.33% |
3,863,239
+383,366
| +11% | +$7.51M |
|
29
Instil Bio
TIL
$196M
| $75.2M | 0.33% |
3,893,700
| – | – |
|
|
30
Legend Biotech
LEGN
$6.64B
| $68.3M | 0.3% |
1,664,534
+1,548,908
| +1,340% | +$63.6M |
|
31
Neurocrine Biosciences
NBIX
$13.5B
| $65.9M | 0.29% |
676,975
| – | – |
|
32
Nurix Therapeutics
NRIX
$723M
| $65.1M | 0.29% |
2,454,082
| – | – |
|
33
Insmed
INSM
$30.3B
| $61.4M | 0.27% |
2,156,001
| – | – |
|
|
ALLK
34
DELISTED
Allakos
ALLK
| $60M | 0.26% |
703,050
| – | – |
|
35
Zymeworks
ZYME
$1.07B
| $59.3M | 0.26% |
1,708,472
| – | – |
|
|
HZNP
36
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $56.1M | 0.25% |
599,110
| – | – |
|
|
FMTX
37
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $50.4M | 0.22% |
2,024,876
| – | – |
|
38
Immatics
IMTX
$662M
| $49.7M | 0.22% |
4,282,938
+290,182
| +7% | +$3.37M |
|
39
Merus
MRUS
$5.04B
| $42.9M | 0.19% |
2,037,469
| – | – |
|
40
Ultragenyx Pharmaceutical
RARE
$3.04B
| $42.4M | 0.19% |
444,444
| – | – |
|
|
ADAP
41
Adaptimmune Therapeutics
ADAP
$13.9M
| $41.9M | 0.18% |
9,830,877
| – | – |
|
42
Krystal Biotech
KRYS
$4.35B
| $41.3M | 0.18% |
607,735
-152,677
| -20% | -$10.4M |
|
43
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $39M | 0.17% |
2,799,577
| – | – |
|
44
Fulgent Genetics
FLGT
$674M
| $37M | 0.16% |
401,016
| – | – |
|
45
Axsome Therapeutics
AXSM
$6.09B
| $36.4M | 0.16% |
539,057
-89,357
| -14% | -$6.03M |
|
46
Neurogene
NGNE
$284M
| $35.3M | 0.15% |
3,821,740
| – | – |
|
47
BioAtla
BCAB
$28.7M
| $35M | 0.15% |
825,000
| – | – |
|
48
ADC Therapeutics
ADCT
$370M
| $34.5M | 0.15% |
1,418,107
| – | – |
|
49
Aligos Therapeutics
ALGS
$75.1M
| $32.8M | 0.14% |
1,610,000
| – | – |
|
|
JBIO
50
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $32.6M | 0.14% |
+1,428,571
| New | +$32.6M |
|